Stockreport

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights [Yahoo! Finance]

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF ENVISION data expected to support completion of UGN-102 NDA in Q3 2024 Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months [Read more]